[Anticoagulant therapy and prognosis in patients with CHF and AF in the setting of real-life clinical practice].
Prevalence of atrial fibrillation (AF) grows with the increase in CHF FC and reaches 45% in III-IV FC CHF. With an adequate anticoagulant (AC) therapy, the risk of thromboembolic complications does not significantly differ between patients with I-II FC and III-IV FC CHF. Of particular interest is studying administration of the anticoagulant treatment and correspondence between the SAMe-TT2R2 scale and actual TTR values in patients with CHF and AF in real-life clinical practice. Toanalyze the efficacy of anticoagulant therapy and prognosis in patients with CHF and AF in the setting of real-life clinical practice. The study included 272 patients with CHF and AF who were discharged from the hospital where they had been treated for decompensated CHF and who were followed up as outpatients for a year. Efficacy of the AC therapy was evaluated; parameters of CHA2DS2-VASc, HAS-BLED, and SAMe-TT2R2 scales were calculated at baseline. TTR was computed to determine the maintenance time. Patients with CHF had permanent (56.3%), persistent (38.6%), or paroxysmal (5.1%) AF. The mean CHA2DS2-VASc score was 3.83±1.16 and the mean HAS-BLED score was 1.3±0.83. SAMe-TT2R2 scores were 0 for 1.6% of patients; 1 for 36.9%, and 2< for 61.5%. At baseline, one third of patients with CHF and AF received antiplatelet therapy (APT) and every forth patient received no therapy. At one year, 69.0% of patients took AC on a constant basis (р.